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performed with snaring maneuver as a bailout in cases of coronary ostia impairment
or severe prosthetic leak due to higher deployment for a suboptimal sealing of the
device with valve calcifications (N=2; 28.6%). The majority of accidental embolization
occurred during early experience with the new Accutrak delivery system. In 6 a second
CRS in the correct position was implanted. The misplaced CRS functioned normally,
with no instances of structural deterioration, thrombosis or further distal migration,
and showed complete apposition against the aortic wall. Moreover, no thromboembolic
events were reported in any patient.
Conclusion: CRS embolization can be effectively managed, implanting a second
prosthesis in a standard fashion and leaving the misplaced device in aorta. There seem
to be no long term vascular or neurological adverse events associated with device
embolization or intentional relocation in experienced hands.
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Background: Currently an efficacy of transcatheter aortic valve implantation (TAVI)
has been proved as a less invasive treatment for high risk elderly patients with aortic
stenosis in Europe and United States, and many patients received TAVI. However, there
is no data regarding to appropriate size of aortic valve by TAVI in Asian population
who has smaller build than those in Europe and United states. To clarify aortic annular
size in Japanese patients with aortic stenosis, the following study was evaluated.
Methods: Between May 2004 and December 2008, consecutive 340 patients (male:
158, female: 182) who underwent surgical replacement of aortic valve for aortic
stenosis were studied. Study subjects included tricuspid anatomy in 224 patients and
bicuspid in 116 patients. Because of indication for TAVI, patients with tricuspid
anatomy were evaluated by TTE (transthoracic echocardiography) and TEE
(transesophageal echocardiography). We analyzed the sizes of annulus and implanted
valve.
Results: Patient age was 72.9±8.4 years old (male) and 75.8±6.8 years old (female).
Annulus diameter was 21.1±2.1 mm (male 22.3±1.9 mm, female 20.3±1.9 mm,
p<0.001). The average annulus diameter above 75 years old also had larger size in
male than female (n=42, 22.3±2.0 mm vs n=82, 20.1±1.8 mm). Implanted valve was
smaller than measured annulus both in male (21.7±1.4 mm) and female (19.3±1.3 mm).
Small size valve bellow 20 mm was counted in 31.5% of whole patients, and 46.3%
of female elderly above 75 years old.
Conclusion: Asian population including Japanese shall need a smaller size of
prosthetic aortic valve in elderly. Furthermore, considering the thickness of sewing
ring of tissue valve, Euro-American population may also require a small size valve in
case of value-in-valve technique.
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Background: Transcatheter aortic valve implantation is a therapeutic alternative for
high-surgical-risk patients with severe symptomatic aortic stenosis. Two models of
prosthesis are currently commercialized in France, which can be implanted either via
a transarterial or a transapical approach. The aim of the study was to evaluate in a
national French registry the early safety and efficacy of transcatheter aortic valve
replacement (AVR) using either the Edwards valves or CoreValve in high-surgical-risk
patients with severe aortic stenosis.
Methods: The multicentre national registry was conducted in 33 centres between
January 2010 and July 2011, under the authority of the French Societies of Cardiology
and Thoracic and Cardio-Vascular Surgery. All the valves implanted in France since
the study period were included. The primary endpoint was mortality at 1 month,
6month, 1 year up to 5 year.
Results: Two thousand and five hundred high-surgical-risk patients (logistic
EuroSCORE ≥20%, STS ≥10%, or contra-indication to AVR) were enrolled. Mean age
was 82+7 years and 43.9% were female. Edwards valves and CoreValve were
implanted in 68 and 32% of patients, respectively. The approaches used were
transarterial (transfemoral: 66%; subclavian: 5%) or transapical in 29%. Device success
rate was xx and mortality was xx, xx, xx respectively at 30 days, 6 month and 12
month. Severe complications included stroke (xx), tamponade (xx), acute coronary
occlusion (xx), and vascular complications (xx). Pacemaker was required in xx. At 1
month, xx of patients were in NYHA class II or less, xx at 6 month and xx at 1 year.
All the result will be receive at the end of August 2011
Conclusion: This prospective registry reflects the real-life experience of transcatheter
aortic valve implantation in high-risk elderly patients in France. This registry is the
first exhaustive and consecutive registry included the 2 types of percutaneous aortic
valves
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Background: The percentage of patients eligible for first-generation balloon-
expandable Edwards SAPIEN valve (Edwards Lifesciences, Irvine, California, USA)
implantation was restricted to definite aortic annulus diameters. Moreover, transfemoral
implantation using this device was limited to patients with large bore iliac-femoral
arteries. This study sought to assess the proportion of patients anatomically suitable
for the current Edwards SAPIEN XT (ES-XT) valve using NovaFlex/E-Sheath delivery
system compared with the past Edwards SAPIEN (ES) valve with RetroFlex 3 delivery
system, including both transfemoral and transapical approaches.
Methods: All high surgical risk patients with severe aortic stenosis referred to our
department as potential candidates for TAVI, underwent transesophageal
echocardiography and angiography of aorta and iliac-femoral arteries in order to assess
anatomical suitability by different approaches. The transfemoral access requirements
for ES/RetroFlex 3 system were a minimal iliofemoral lumen diameter of at least 7
mm for the 22-F/23-mm device and a minimal iliofemoral dimension of at least 8 mm
for the 24-F/26-mm device. The current ES-XT with NovaFlex/E-Sheath delivery
system requires a minimal iliofemoral dimension of at least 6 mm for the 23 mm valve
(NovaFlex 18F/E-Sheath 16F) and 6.5 mm for the 26 mm valve (NovaFlex 19F/ E-
Sheath 18F). The range of annulus diameter considered amenable for implantation was
18-25 mm for the ES valve (23 and 26 mm prosthesis) and 18-27.5 mm for ES-XT
valve (23, 26 and 29 mm prosthesis). Transfemoral approach was considered as the
first option, if not suitable the patient was evaluated for transapical approach.
Results: Data were collected for 293 high-risk patients evaluated for TAVI. Anatomic
suitability was 82% (240/293) for ES RetroFlex versus 95% (277/293) for ES-XT
NovaFlex/E-Sheath. Among 240 patients eligible for ES RetroFlex, 80 (33%) were
suitable for transfemoral implantation, while among 277 patients eligible for ES-XT,
those suitable for tranfemoral approach were 172 (62%).
Conclusion: Using current Edwards devices the percentage of patients suitable for
TAVI increases from 82% to 95%. Moreover, while only 1/3 of patients had anatomic
criteria suitable for the less-invasive transfemoral approach with the previous devices,
with the current Edwards SAPIEN devices this proportion increases to about 2/3 of
patients.
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Background: Although impaired LV function may be considered a contra-indication
for aortic valve replacement, the hemodynamic characteristics of transcatheter valves
may offer procedural and long-term clinical benefit in such patients. We sought to
determine the prevalence of impaired LV systolic function and its impact on the in-
hospital and long-term outcome in patients who underwent Transcatheter Aortic Valve
Implantation (TAVI).
Methods: 230 consecutive patients underwent TAVI with the Medtronic-CoreValve
System. Impaired LV function was defined by LVEF ≤35% (European Multicenter
Study on Operative Risk Stratification and Long-term Outcome in patients with Low-
Flow/Low-Gradient Aortic Stenosis). Study endpoints were defined according to the
Valve Academic Research Consortium recommendations.
Results: Compared to patients with a LVEF >35% (n=197), those with LVEF ≤35%
(n=33) were more often male (78.8 % vs. 46.7%, p<0.001), more symptomatic (NYHA
class III / IV, 97.0% vs. 77.2%, p=0.008) and had a higher prevalence of prior coronary
artery disease (63.6% vs. 43.1%, p=0.029). The Logistic EuroSCORE was 14.8% and
22.8%, respectively (p=0.012). No difference was observed between the 2 groups in
in-hospital or 30-day mortality (3.0% vs. 9.6%, p=0.21), the Combined Safety Endpoint
at 30 days (24.2% and 24.4% p=0.99) and survival free from readmission at 2 years
(61.5% and 59.3%). After adjustment, LVEF ≤ 35% was not associated with an
increased risk of 30-day mortality, in-hospital complications and survival free from
readmission at follow-up.
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